OPK Opko Health Inc

$OPK market maker is about to flip to grind up. They don’t short into institutional. Plus some hedging and stuff for calls. Makes me happy. 😁

$OPK • ModeX Is the $12 Ticket: Five distinct multi-specific antibody molecules are moving through development. If even one Phase 1/2 clinical trial demonstrates that ModeX's multispecific antibodies successfully target and wipe out hard-to-treat liquid or solid tumors safely, the underlying value of the pipeline multiplies by billions, not millions.

$OPK biotefeence was the reason this company fell short, it bled them out and was never profitabke.. now its sold & they sit on close to 1 billion in cash with a pipeline and new strategic focus on drug development and partnering with other biotechs. Good things coming imo now that they are out of diagnostics.

$OPK with opko trading at some of its highest prices for the year, i dont think we will need to be too concerned about year end selling pressure due to tax loss harvesting!! thats a good thing for us longs! some investors will be looking for stocks in this situation going into the end of the year. high tech may have a problem.

$OPK STRONG BUY is the rating that Zacks continues to flaunt for Opko in article after article! I AGREE! GO OPKO!

$OPK please be advised the price target for OPKO is being raised to double of any analysts' price target 2X's!! analysts know nothing!! GO OPKO!!

$OPK Why ModeX is not a typical biotech flop: ​Merck is paying: Merck is fully funding and running the clinical trials for the EBV vaccine. They take the risk, not shareholders. ​Free government cash: The US government (BARDA) is giving them tens of millions in non-dilutive funding for COVID and flu. ​Advanced tech: Their multi-specific antibodies hit 3 or 4 targets at once, preventing cancer and viruses from mutating and escaping the drug. ​ModeX is validated and funded by Merck, Regeneron, and the US government, not by retail share dilution.

$OPK OPK has almost 1 BILLION in CASH after the deal is closed! I’d think we’d see 3-4$ out of this! Somatrogon sales growth seems to add 2m$ in additional revenue per qtr. Then after the end of 2026… no more BioReference marginalization on earnings. True, BR CV19 testing saved OPK during Somatrogon multi delayed commercialization but as of late… the testing losses gave the earnings a bad case of the flu. OPK really chased the cheddar during CV19 and did quite well for themselves, but it’s time to unload and let the big boys run with it.

$OPK Earnings soon and fingers crossed the notes are retired with cash and shorts cover!

$OPK Early buyers here (especially those who bought before the closing bell on Friday last week) will catch tomorrow Monday’s rocket. Now it’s time to school the bears and uneducated bulls: The "Monday Effect" Reversal: Options expire on Fridays. On the following Monday, a wave of new capital or rolled-over positions often enters the market, frequently triggering a relief rally if the stock was heavily suppressed into expiration week. When a stock experiences this post-expiration rally, it is often due to the unwinding of institutional trading positions, particularly through a process known as "gamma squeezing" or market maker hedging. The best part of it all is the raft of PT increases and unanimous buy consensus upgrade, so we are talking a climb of between $2 to $3

$OPK It’s been a volatile day, but volatility is exactly why I’m here . I think today’s price action in OPK is especially telling.

$OPK You’ll have to go mad and be confined to the asylum where you belong before that’ll happen.

$OPK We did a deep dive on OPKO Health. • Most labs go to Labcorp; unit lost $13.0M in Q1, Q2 profit took an $18.1M one-off earnout • Kept drug arm loses ~$29M/qtr • Next: antitrust; Labcorp owes $28.88M if blocked; Apr 14, 2027 deadline Full report linked in the replies.

$OPK For anyone wondering about yesterday’s drop, I haven’t found any new negative company or ModeX news that explains it. The convertible-note conversion window could be creating some dilution/selling concern, but that’s only a possibility. Meanwhile, Zacks itself confirmed Monday that OPK is now a Zacks Rank #1 (Strong Buy). No new negative MDX2001, Merck EBV, BARDA or other ModeX development that I can find. For now, yesterday looks more like market/share-structure pressure than a change in the underlying story.

$OPK Let’s pay off those notes Frosty and Rock the share price. You can take that note cash and buy more OPK shares :)

$OPK OPKO’s CEO, Phillip Frost, reported roughly 255 million shares in beneficial ownership—around 34%. That’s massive exposure, and I suspect he’s underwater on a good chunk of it, although I don’t know his average cost. After the business sale, I’d expect him to come out swinging at tomorrow’s earnings: a share buyback, debt repurchases, or something meaningful to get the stock moving. With this technical setup, failing to capitalize would feel like missing the opportunity of a lifetime. Either that or he’s hedged big time 😂 Just my speculation.

$OPK I don’t put too much weight on these ratings, but yeah, 8/10 is a very good score. I definitely expect shakeouts on the way up. In my view, traders with the patience and guts to buy those dips could be well rewarded. This looks like a solid trading vehicle for the next two to three months.

$OPK Sold at 1.80 Shared it in my email group ( Thursday email) Not bad in unstable market. Best of luck for everyone!

$OPK $722M + an additional $150M earn out based on revenue of unit. So at total of $872M potential while its market cap was just $1B yesterday

$OPK Modex came in 4 years ago and walked into a mess from all directions. They have been cleaning house and restructuring ever since. What opko was 10/20 years ago is not what it is today. Modex has redefined everything and in time, we opko bag holders will reap the benefits. Not sure why the ticker opk hasn't been replace with mdx. JMO